Understanding clinical trial outcomes: Design, analysis, and interpretation

Dermatologic Therapy

Volumn 20, Issue 2, 2007, Pages 77-85

  Jacobe, Heidi T ^a   Leitenberger, Justin J ^a   Bergstresser, Paul R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Clinical trial design; Outcome measure; Statistical analysis

Indexed keywords

FLUORIDE;

ACCURACY; ANALYSIS OF VARIANCE; BIOSTATISTICS; CLINICAL TRIAL; COMPARATIVE STUDY; DERMATOLOGY; ECONOMIC ASPECT; HUMAN; KAPLAN MEIER METHOD; KRUSKAL WALLIS TEST; OSTEOPOROSIS; OUTCOME ASSESSMENT; PSORIASIS; QUALITATIVE ANALYSIS; QUALITY OF LIFE; RANK SUM TEST; RELIABILITY; REVIEW; STATISTICAL ANALYSIS; STUDENT T TEST; TECHNOLOGY; VALIDATION PROCESS; VALIDITY;

CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 34249307320     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00115.x     Document Type: Review

References (14)

1. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 1997 : 16 : 2529 2542.
2. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004 : 291 : 2457 2465.
3. Lachin JM. The role of measurement reliability in clinical trials. Clin Trials 2004 : 1 : 553 566.
4. Streiner DL, Norman GR. "Precision" and "accuracy": two terms that are neither. J Clin Epidemiol 2006 : 59 : 327 330.
5. Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. New York : Houghton Mifflin Company, 2002.
6. Greenhalgh T, ed. How to Read a Paper. London : Blackwell Publishers, 2006 : 212.
7. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999 : 282 : 790 795.
8. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989 : 8 : 431 440.
9. Riggs BL. A new option for treating osteoporosis. N Engl J Med 1990 : 323 : 124 125.
10. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled Ann Intern Med 1996 : 345 : 605 613.
11. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet 1995 : 345 : 1616 1619.
12. Zaf JH. Biostatistical Analysis. 4th ed. Upper Saddle, NJ: Prentice Hall, 1999.
13. Sampogna F, Tabolli S, Soderfeldt B, Axtelius B, Aparo U, Abeni D. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol 2006 : 154 : 844 849.
14. Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001 : 45 : 72 76.